Ding YJ, Chang TS, Shen CH, Kuo LM, Hsu SL, Chen YH, Hsieh YY, Huang HL, Lu SN*. Survival benefit of sequential curative treatment for TACE suitable BCLC stage B HCC patients. Sci Rep. 2024 Sep 29;14(1):22588.
Huang HL, Chang TS, Canseco LM, Wu F*, Lu SN*. Role of reimbursement and Physicians' awareness in the survival of sorafenib-eligible advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci. 2024 Jun;40(6):589-598. doi: 10.1002/kjm2.12838. (SCI)
Chen CH, Hsu NT, Chen IC, Chang TS, Cheng S, Cheng SY, Chen HM, Harn MR, Liu CK, Yang MT, Lu SL, Tseng CM*, Lu SN*. Dual strategy involving hospital-based study and community-based screening to eliminate hepatitis C in remote areas. J Formos Med Assoc. 2024 May; 123(5): 613-619. (SCI)
Wang JH, Ou HY, Yen YH, Hung CH, Lu SN*. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease. Liver Int. 2023 Sep;43(9):1901-1908. (SCI)
Yao CC, Wang JH, Chen CH, Hung CH, Yen YH, Kee KM, Hu TH, Tsai MC, Kuo YH, Lu SN*. Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Diagnostics. 2023 Feb;13(4):696. (SCI)
Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC, Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, Tseng HP, Chiang CJ, Lu SN*. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses. 2022 Dec 31;15(1):126. (SCI)
Chang TS, Hsu NT, Chen SC, Hsu IL, Lee MH, Lu SN*. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses. 2022 May 7;14(5):984.(SCI)
Chuang PH, Lu SN*. Sequential treatment after transcatheter arterial chemoembolization for patients with single large hepatocellular carcinoma. Adv Dig Med. 2022;9:141-143. (EDITORIAL) 台灣消化醫學雜誌 (non-SCI)
Wu CH, Huang WC, Chen CH, Lu SN*. Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers. Biomed J. 2022 Oct;45(5):798-805. (SCI)
Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN*. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc. 2022 Oct;121(10):2085-2092. (SCI)
Kee KM, Chen WM, Hsu NT, Wang JH, Chao WH, Lin YC, Lu SN*. Community-based screening by Anti-HCV reflex HCV Ag test and accessible post-screening care toward elimination of hepatitis C in two hyperendemic townships. J Formos Med Assoc. 2022 Sep;121(9):1850-1856. (SCI)
Tien HM, Cheng TC(co-first), Lien HC, Yang KF, Shy CG, Chen YL, Hsu NT, Lu SN*, Wang JH*. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care. Int J Environ Res Public Health. 2022 Mar 10;19(6):3269. (non-SCI)
Huang WC, Lin YC, Chen PJ, Hsu NT, Tu CL, Chang TS, Hung CH, Kee KM, Chao WH, Lu SN*. Community-Based Screening for Hepatitis B and C Infectivity Using Two Quantitative Antigens to Identify Endemic Townships. Viruses. 2022 Feb 1;14(2):304. (SCI)
Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN*, Kuo YH*. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci. 2021 Oct;37(10):894-902. (SCI)
Chang TS, Chang KC, Chen WM, Hsu NT, Lee CY, Lin YC, Huang WC, Chiu WN, Hu JH, Huang TJ, Chen MY, Lu SN*. Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. BMJ Open. 2021 Jul 7;11(7):e046115. (SCI)
Wu GH, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS, Lu SN*. The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. J Formos Med Assoc. 2021 July ; 120(7): 1444-1451. (SCI)
Chen WM, Lee CY, Hsu NT, Huang WC, Chen MY, Huang TJ, Lu SN*. Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community. J Formos Med Assoc. 2021 May;120(5):1237-1241. (SCI)
Lu SN*, Wu HM, Pwu RF. : Alternate title: Epidemiology-based precise hepatitis C pilot control programs leads the official national screening. Taiwan Journal of Public Health. 2021 Apr; 40(2):123-126.
台灣公共衛生雜誌 (政策論壇 Policy Forum)
Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN*. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc . 2021 Feb;120(2):847-853. (SCI)
Tsao CF, Chang CM, Weng SW, Wang PW, Lin CY, Lu SN. Identifying endemic areas and estimating the prevalence of hyperlipidemia in Taiwan's townships. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):460-465. (SCI)
Chen YY, Chen CL, Chen JW, Hsu NT, Wei ST, Hou SM, Lu SN*, Chen PJ*. Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017. Hepatol Commun. 2020 Jun 4;4(8):1193-1205.
Wang JH, Ou HY, Yen YH, Chen CH, Lu SN*. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. Dig Dis Sci. 2020 May;65(5):1512-1519. (SCI)
Wang JH, Chen CH, Chang CM, Feng WC, Lee CY, Lu SN*. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan. J Formos Med Assoc. 2020 Jan;119(1 Pt 3):504-508. (SCI)
Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN*. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019 Nov;35(11):708-714. (SCI)
Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN*. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One. 2019 Oct 22;14(10):e0222196. (SCI)
Lu SN. Liver Tumor Ablation Assisted by Image Fusion. J Med Ultrasound. 2019 Apr-Jun;27(2):61-62. (Non-SCI) 醫用超音波雜誌
Kuo YH, Lu SN*. Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. Aliment Pharmacol Ther. 2019 Jan;49(2):233-234. (SCI)
Chang C, Hung CH, Wang JH, Lu SN*. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci. 2018 Dec;34(12):684-688. (SCI)
Kuo YH, Lu SN*. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors' reply. Aliment Pharmacol Ther. 2018 Nov;48(10):1162-1163. (SCI)
Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, Lu SN*. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002 (SCI)
Yen CW, Kuo YH, Wang JH, Chang KC, Kee KM, Hung SF, Chen Y, Tsai LS, Chen SC, Hung CH, Lu SN*. Did AFP-L3 save ultrasonography in community screening? Kaohsiung J Med Sci. 2018 Oct;34(10):583-587. (SCI)
Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN*. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs. 2018 Apr;36(2):307-314. (SCI)
Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN*. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981. (SCI)
Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, Lu SN*. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. Sci Rep. 2017 Apr 27;7(1):1212.(SCI)
Kee KM, Lu SN*. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):277-279. (Editorial)
Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN*. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. PLoS One. 2016 Dec 9;11(12):e0166543. (SCI)
Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int. 2016 Dec;36(12):1793-1799.(SCI)
Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN*. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. Sci Rep. 2016 Jul 22;6:30156. (SCI)
Yeh JH, Hung CH, Wang JH, Kuo YH, Tai WC, Lu SN*. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter? Dig Liver Dis. 2016 June;48(6):661-666. (SCI)
Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. PLoS One. 2016 May 13;11(5):e0155544. (SCI)
Wang JH(co-first), Chen TY(co-first), Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF, Lu SN*. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. Dig Dis Sci. 2016 Apr;61(4):1197-205. (SCI)
Yap YS, Chuang KW, Chiang CJ, Chuang HY, Lu SN*. Geographic Variation of Chronic Kidney Disease Prevalence: Correlation with the Incidence of Renal Cell Carcinoma or Urothelial Carcinoma? Biomed Res Int. 2015;2015:427084. (SCI)
Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN*. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One. 2015 Dec 14;10(12):e0144893. (SCI)
Kuo YH, Lu SN*. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. Kaohsiung J Med Sci. 2015 July; 31(7):386-387. (SCI)
Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, Lu SN*. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. PLoS One. 2015 May 13;10(5):e0126031. (SCI)
Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN*. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol. 2015 Feb;30(2):358-63. (SCI)
Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Lu SN*. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort. Kaohsiung J Med Sci. 2015 Feb; 31(2): 102–107. (SCI)
Lee MH*, Lu SN*, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ*; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014 May 6;9(5):e94760. (SCI)
Kee KM, Hung CH, Wang JH, Lu SN*. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. OncoTargets and Therapy. 2014 May;7:829-834. (SCI)
Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN*. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013 Sep;58(9):2721-8. (SCI)
Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response. Dig Dis Sci. 2013 Feb;58(2):556-61. (SCI)
Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN*. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci. 2013 Aug;29(8):451-9. (SCI)
Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN*. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013 Jul;29(7):385-95. (SCI)
Wang JH, Lu SN*. Response to Giannini et al. Am J Gastroenterol. 2013 Jul;108(7):1175. (SCI)
Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013 June;7(2):477-488. (SCI)
Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN*. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013 Mar;108(3):416-24. (SCI)
Wang JH, Wang CC(co-first), Hung CH, Chen CL, Lu SN*. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012 Feb;56(2):412-8. (SCI)
Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, Lu SN*. Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus. J Gastroenterol Hepatol. 2012 Nov;27(11):1688-94. (SCI)
Lu SN. Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. J Gastroenterol Hepatol. 2012 Jun;27(6):991-3. (SCI)
Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN*. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012 Jun;50(6):1989-93. (SCI)
Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN*. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012 Jun;27(6):1106-11. (SCI)
Kee KM, Lu SN*. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011;81 Suppl 1:36-40. (SCI)
Tsai PS, Chang CJ, Chen KT, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai CC, Lu SN*. Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int. 2011 Aug;31(7):971-9. (SCI)
Chen CT, Kuo YH, Huang CF, Huang CF, Lu SN*. Treatment Effects of Standard of Care for Chronic Hepatitis C in Real World: A Personal Experience of A Hepatologist in A Medical Center in Southern Taiwan. J Intern Med Taiwan 2011 June; 22(3): 192-198. 內科學誌
Hung CH, Lee CM, Lu SN*. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011 May;9(5):525-33. Review. (SCI)
Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN*. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. (SCI)
Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN*. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011 May 15;128(10):2344-52. (SCI)
Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai PS, Tsai CC, Lu SN*. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol. 2011 Jan;26(1):129-34. (SCI)
Wang JH, Tung HD, Chen TY, Hung CH, Chen CH, Changchien CS, Hu TH, Lee CM, Lu SN*. Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin. Hepatol Int. 2011 Mar; 5(1): 567-574. (SCI)
Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN*. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010 Nov;25(11):1763-8. (SCI)
Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, Lu SN*. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010 Aug;25(8):1426-34. (SCI)
Kee KM, Hung CM, Wang JH, Hung CH, Chen PF, Lin KS, Lu SN*. Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995-2004. J Gastroenterol Hepatol. 2010 Jul;25(7):1289-94. (SCI)
Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010 May;25(5):964-9. (SCI)
Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, Lu SN*. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. J Gastroenterol. 2010 Jun;45(6):636-45. (SCI)
Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN*. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol. 2010 Mar;105(3):624-31. (SCI)
Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, Lu SN*. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010 Mar;25(3):605-12. (SCI)
Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN*. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatol Int. 2009 Dec;3(4):537-43. (SCI)
Chiang JC, Lin CY, Wang JH, Kee KM, Chen PF, Chen YD, Tsai LS, Chen TH, Lu SN*. Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation. Trans R Soc Trop Med Hyg. 2009 Sep;103(9):917-23. (SCI)
Lin CY, Kee KM(co-first), Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lu SN*. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009 Jan;29(1):74-81. (SCI)
Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN*. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009 Jun;41(6):431-41. (SCI)
Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009;44(5):439-46. (SCI)
Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN*. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1155-63. (SCI)
Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN*. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009 Mar 13;27(12):1858-62. (SCI)
Kao JT, Wang JH, Hung CH, Hu TH, Lee CM, Hung SF, Lu SN*. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver Int. 2008 Nov;28(9):1298-304. (SCI)
Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN*. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008 May;44(7):1000-6. (SCI)
Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN*. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43(2):159-70. (SCI)
Lu SN, Yen YH, Lin CY, Kee KM, Wang JH, Changchien CS*. Clinical Staging of Hepatocellular Carcinoma. Journal of The Chinese Oncology Society 2008 Oct. 24(5):295-303. 中華民國癌症醫學會雜誌
Lu SN*, Wang JH, Chen PF, Tung HD, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Tsai LS, Chen TH. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1813-21. (SCI)
